Stephen Silberstein, MD

Stephen Silberstein, MD

Contact Dr. Silberstein

900 Walnut Street
Second Floor
Philadelphia, PA 19107

(215) 955-2243
(215) 955-2060 fax

Most Recent Peer-reviewed Publications

  1. Early onset of effect of onabotulinumtoxinA for chronic migraine treatment: Analysis of PREEMPT data
  2. Adherence to the 2008 IHS guidelines for controlled trials of drugs for the preventive treatment of chronic migraine in adults
  3. Differential efficacy of non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A meta-analysis
  4. Galcanezumab in episodic migraine: Subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)
  5. The endocannabinoid system in migraine: from bench to pharmacy and back
  6. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials
  7. Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study
  8. Rationale for electrical parameter determination in external trigeminal nerve stimulation (eTNS) for migraine: A narrative review
  9. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine
  10. Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
  11. Current Status of Antiepileptic Drugs as Preventive Migraine Therapy
  12. Invited Commentary on Preventive Anti-Migraine Therapy (PAMT)
  13. Development of a claims-based algorithm to identify potentially undiagnosed chronic migraine patients
  14. The Effect of Beginning Treatment With Fremanezumab on Headache and Associated Symptoms in the Randomized Phase 2 Study of High Frequency Episodic Migraine: Post-Hoc Analyses on the First 3 Weeks of Treatment
  15. Fremanezumab for the preventive treatment of migraine
  16. Vestibular Neuroscience for the Headache Specialist
  17. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
  18. Long-term safety and tolerability of erenumab: Three-plus year results from a five-year open-label extension study in episodic migraine
  19. Migraine Headache: Diagnosis and Current and Emerging Preventive Treatments
  20. Erenumab in the treatment of migraine